Two innovations grants awarded to RI-MUHC research leaders

(McGill University Health Centre) The Research Institute of the McGill University Health Centre (RI-MUHC) is pleased to announce that Dr. Morag Park and Dr. Alain Ptito, both RI-MUHC members, have been awarded major grants to advance their innovative work in the areas of cancer therapy and brain injuries respectively. These research grants were part of a national investment of $333 million for research infrastructure through the Canada Foundation for Innovation.
Source: EurekAlert! - Biology - Category: Biology Source Type: news

Related Links:

Source: Clinical Trials And Noteworthy Treatments For Brain Tumors - Category: Cancer & Oncology Source Type: clinical trials
In conclusion, BP/LPPC can inhibit growth of melanoma cells and induce cell arrest and apoptosis, indicating that BP/LPPC has great potential for development of melanoma therapy agents.
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
This article, however, is more of a commentary on high level strategy and the effects of regulation, coupled with a desire to forge ahead rather than hold back in the matter of treating aging, thus I concur with much more of what is said than is usually the case. For decades, one of the most debated questions in gerontology was whether aging is a disease or the norm. At present, excellent reasoning suggests aging should be defined as a disease - indeed, aging has been referred to as "normal disease." Aging is the sum of all age-related diseases and this sum is the best biomarker of aging. Aging and its d...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSION: The usage of subthreshold concentrations of muscarinic agonists combined with conventional chemotherapeutic agents could be a promising tool for breast cancer therapy. PMID: 30501602 [PubMed - as supplied by publisher]
Source: Current Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Clin Pharmacol Source Type: research
UCLA researchers have found that commonly used hormone therapies for women diagnosed with breast cancer do not appear to cause significant cognitive dysfunction following the treatment.Endocrine therapy has become an essential part of treatment for the many women diagnosed with hormone-receptor positive breast cancer, in which hormones, such as estrogen, promote cancer growth. The endocrine treatment helps lower the recurrence and reduce the risk of death from breast cancer by interfering with how a woman ’s own hormones can continue to support the growth of dormant cancer cells. Yet, there has been limited evidence ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
CONCLUSIONS:Our findings suggest that LMWH might represent an effective and safe strategy for the management of CVT in cancer patients. The findings are consistent with results from large randomized trials for outcomes of cancer associated venous thrombosis in other anatomical locations. The impact of thrombus recanalization in recurrent thrombosis and bleeding outcomes deserves further exploration. Limitations to our study are the retrospective and non-randomized design for the adjudication of treatment agents.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 332. Antithrombotic Therapy Source Type: research
Endogenous thymic regeneration is a crucial function that allows for renewal of immune competence following immunodepletion caused by common cancer therapies such as cytoreductive chemotherapy or radiation; however, the mechanisms governing this regeneration remain poorly understood. Despite this capacity, prolonged T cell deficiency is a major clinical hurdle in recipients of hematopoietic stem cell transplantation (HSCT) and can precipitate high morbidity and mortality from opportunistic infections, and may even facilitate malignant relapse. Our recent studies have revealed that innate lymphoid cells (ILCs) and endotheli...
Source: Blood - Category: Hematology Authors: Tags: 701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Signaling Pathways and Cells Protecting Against GVHD Source Type: research
Abstract Glioblastoma (GBM) is a devastating disease with an extremely poor prognosis. Immune therapy via adoptive cell transfer (ACT), especially with T cells engineered to express chimeric antigen receptors (CARs), represents a particularly promising approach. Despite the recent success of CAR T cells for blood cancers, the question remains whether this powerful anti-cancer therapy will ultimately work for brain tumors, and if the primary immunologic challenges in this disease-which include antigenic heterogeneity, immune suppression and T-cell exhaustion-can be adequately addressed. Here, we contextualize these...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Publication date: January 2019Source: Biomedicine &Pharmacotherapy, Volume 109Author(s): Xin Zhang, Kaikai Ding, Jian Wang, Xingang Li, Peng ZhaoAbstractGlioblastoma multiforme (GBM) is the most common and aggressive primary human brain tumor. Although comprehensive therapies combining radiotherapy and chemotherapy after surgery can prolong survival, the prognosis is still poor with a median survival of only 14.6 months. Chemoresistance is one of the major causes of relapse as well as poor survival in glioma patients. Therefore, novel strategies to overcome chemoresistance are desperately needed for improved treatment ...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Membrane type ‐1 matrix (MT1‐MMP) metalloproteinase is highly expressed in glioblastoma. Inducing cancer cell autophagy may contribute to cancer therapy. We found that ARP101 exploits MT1‐MMP's signal transducing functions to trigger autophagy in a highly invasive glioblastoma cell line model. ARP101 may be envisioned in future therapy modalities against brain cancer. AbstractMembrane type ‐1 matrix metalloproteinase (MT1‐MMP) possesses both extracellular proteolytic and intracellular signal‐transducing functions in tumorigenesis. An imbalance in MT1‐MMP expression and/or function triggers a metastatic, invas...
Source: Chemical Biology and Drug Design - Category: Biology Authors: Tags: RESEARCH ARTICLE Source Type: research
More News: Biology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Therapy | Grants | Health | Neurology